2 Deeths MJ, Chapman JT, Dellavalle RP et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol 2005; 52:275-80. 3 Didona B, Benucci R, Amerio P et al. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 2004; 150:1198-201. 4 Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768-85. 5 Schon M, Bong AB, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95:1138-49. 6 Urosevic M, Maier T, Benninghoff B et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139:1325-32. 7 Schon MP, Wienrich BG, Drewniok C et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004; 122:1266-76. 8 Coors EA, Schuler G, von den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol 2006; 16:391-3.SIR, Calcinosis cutis refers to cutaneous deposition of calcium salts in the skin. It may be classified as metastatic, dystrophic, idiopathic or iatrogenic type based on the aetiopatho-